Profound Medical Revenue Climbs 86% To $9.8 Million — But Its Loss Barely Shrinks
Operating cash use fell 56% from the second quarter as Profound added a U.S. equipment distribution channel through Cook Medical.
Profound Medical, which makes MRI-guided ultrasound devices that destroy diseased tissue without incisions, reported approximately $9.8 million in third-quarter revenue Thursday, up 86% from a year earlier, according to the earnings release accompanying its SEC filing. Its net loss narrowed just 3% to approximately $7.7 million as operating expenses rose 21%.
Equipment Sales Lead The Growth
Equipment brought in $5.7 million, while single-use devices and extended-warranty services generated $4.1 million. Profound reported a 78% gross margin, compared with 74% a year earlier, crediting the mix of products sold and its pricing discipline.
Operating expenses reached approximately $15.5 million. Staffing, sales commissions, travel, severance and research consulting increased costs; the research spending targeted cheaper products and more efficient operations. Completing enrollment in the CAPTAIN clinical trial reduced trial spending, partly offsetting those increases.
The quarterly loss was $0.21 per share, compared with approximately $8.0 million, or $0.26 per share, a year earlier. Operating cash use showed a much larger improvement: approximately $5.0 million, down 56% from $11.3 million in the second quarter and 48% from $9.6 million a year earlier.
Profound expects at least $25.0 million in 2026 revenue and a gross margin of 70% or higher. Quarter-end cash was approximately $33.3 million, which management expects, together with sales, to fund operating and capital spending for at least the next 12 months. The company said it has no immediate capital-raising plans but will consider financing both with and without issuing shares.
Cook Adds An Equipment Sales Route
Profound's TULSA-PRO treats prostate tissue, including cancer and benign enlargement; Sonalleve treats conditions including uterine fibroids and certain bone tumors. Equipment placements also create a market for the company's single-use treatment devices and services.
TULSA-PRO's installed base reached 98 systems at quarter-end, and the 5,000th TULSA Procedure took place in October. Approximately 10.7 million people gained payer coverage during the quarter, including approximately 1.8 million through commercial and Medicare Advantage programs.
Cook Medical's Copernicus program supplies another route to U.S. equipment buyers under an agreement signed last week. Cook will buy systems from Profound for distribution alongside its iMRI Suite; customers will buy disposables and service directly from Profound. Profound's sales team will continue selling to sites with compatible MRI scanners.
The arrangement complements a co-sales and co-marketing agreement with Siemens Healthineers involving its MAGNETOM Free.Max scanner. Profound is seeking FDA clearance for that combination; TULSA-PRO already has clearance for multiple compatible 1.5T and 3T MRI systems.
Prospective TULSA-PRO and Sonalleve deals in the company's qualified sales pipeline totaled approximately $79.2 million at quarter-end. Those opportunities are at verification, negotiation or contracting stages—not recognized revenue, and their conversion and timing are not assured. An October co-education agreement with Telix Pharmaceuticals also aims to broaden physician awareness of TULSA-PRO and its role alongside prostate cancer imaging.
Fabian Will Take The Helm
President Richard Fabian will become CEO on January 14, 2027. CEO and Chairman Arun Menawat will move to executive chairman under the planned succession.
"My priority is to scale this organization," Fabian said. He identified commercial and clinical operations, supply chain and innovation as areas that must support growth.
Matthew Sobczyk became permanent chief financial officer effective immediately. Jason Mills, executive vice president of strategy at Penumbra, joined the board, replacing Cynthia Lavoie, who stepped down.
Profound says one-year CAPTAIN clinical outcomes remain on track for presentation at the Radiological Society of North America's annual meeting in Chicago, scheduled for November 29–December 3, 2026.
Sources
- 8-K Filing — Profound Medical Corp. (PROF) — SEC EDGAR
- Exhibit exh_991.htm — Profound Medical Corp. 8-K exhibit — SEC EDGAR
- Profound Medical projects at least $25M 2026 revenue as Cook Medical channel ramps in 2027 (TSX:PRN:CA) | Seeking Alpha — seekingalpha.com
- Profound Medical expands U.S. sales network through Cook Medical partnership (PROF:NASDAQ) — seekingalpha.com
- Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth - The Globe and Mail — theglobeandmail.com
- Profound Medical Reports Strong Third Quarter 2026 Results; — globenewswire.com
More on Profound Medical
- Profound Medical CEO Arun Menawat To Become Executive Chair In January, And The Company Retires Its Index 20 Gauge
- Profound Medical Books Montel Williams For Prostate Webinar, Plus Its First VA TULSA-PRO Install
- Profound Medical Signs Co-Education Deal With Telix To Pair PSMA-PET Imaging With TULSA-PRO